

Insulet Corporation Class Action Lawsuit

U.S. Securities Litigation

Insulet Lawsuit Overview

The Insulet class action lawsuit asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Insulet securities. The class action is pending in the U.S. District Court for the District of Massachusetts. It is captioned *Hu v. Insulet Corporation et al.*, No. 26-cv-13062.

If you lost money on your Insulet investment, you are encouraged to submit your information using the form on this page. You may also email adam@bfalaw.com or call 212.789.3619.

Why is Insulet Being Sued for Securities Fraud?

Insulet has been sued for securities fraud following significant stock drops resulting from potential violations of the federal securities laws. The decline in Insulet's stock price caused significant losses to investors.

Insulet is primarily engaged in the development, manufacture, and sale of insulin delivery systems for people with insulin-dependent diabetes through its Omnipod platform. The Omnipod platform includes: the Omnipod® 5 Automated Insulin Delivery System ("Omnipod 5"), the Omnipod DASH® Insulin Management System ("Omnipod DASH"), and the Omnipod Insulin Management System ("Omnipod Eros").

Throughout the relevant period, Insulet misrepresented the safety of its Omnipod products as well as its ability to efficiently produce "medical grade quality at consumer electronic scale." In reality, certain of Insulet's products suffered from undisclosed manufacturing defects that put patient safety at risk.

Why did Insulet's Stock Drop?

On March 12, 2026, Insulet disclosed that a manufacturing issue with its Omnipod® 5 Pods caused a "tear in the internal tubing that delivers insulin" resulting in insulin being released inside the Pod "instead of being fully infused

into the body as intended.” Accordingly, Insulet “initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods.”

This news caused the price of Insulet stock to drop \$16.23 per share, or 6.88%, from a closing price of \$236.07 per share on March 12, 2026, to \$219.84 per share on March 13, 2026.

On May 26, 2026, Insulet announced another voluntary Medical Device Correction due to a manufacturing issue, this time to its Omnipod 5, Omnipod DASH, and Omnipod Eros systems. It again indicated that the manufacturing issue resulted in a tear in the tubing which “could result in insulin under-delivery.”

This news caused the price of Insulet stock to drop \$7.79 per share, or 5.07%, from a closing price of \$218.11 per share on May 26, 2026, to \$146.01 per share on May 27, 2026.

Insulet (\$PODD) Stock Chart



Image Caption: NASDAQ online chart showing the Insulet (\$PODD) stock drop following the May 2026 announcements.

What is the Insulet Leadership Deadline?

You may ask the Court no later than August 31, 2026, to appoint you as Lead Plaintiff through counsel of your choice.

To be a member of the Class, you need not take any action at this time. The ability to share in any potential future recovery is not dependent on serving as Lead Plaintiff.

How Do I Submit My Information?

If you lost money when Insulet securities dropped in price, you are encouraged to submit your information using the form on this page to speak with an attorney about your rights.

You can also contact:

Adam McCall
amccall@bfalaw.com
212.789.3619

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of any class action lawsuit. The firm will seek court approval for any potential fees and expenses.

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by *Chambers USA*, *The Legal 500*, and *ISS SCAS*.

BFA attorneys have been named “Elite Trial Lawyers” by the *National Law Journal*, “Litigation Stars” by *Benchmark Litigation*, among the top “500 Leading Plaintiff Financial Lawyers” by *Lawdragon*, “Titans of the Plaintiffs’ Bar” by *Law360*, and “SuperLawyers” by *Thomson Reuters*.

Most recently, *The Legal 500* awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”

BFA's notable successes include a recovery of over \$900 million in value from Tesla, Inc.'s Board of Directors, as well as \$420 million from Teva Pharmaceutical Ind. Ltd.
Attorney advertising. Past results do not guarantee future outcomes.